Background & Aims Non-alcoholic steatohepatitis (NASH) is a chronic, progressive fibrotic
liver disease that can lead to cirrhosis. While liver biopsy is considered the reference …

Abstract Background & Aims Non‐invasive biomarkers are needed for monitoring changes
in liver histology in patients with non‐alcoholic steatohepatitis (NASH). Obeticholic acid …

Background and Aims Nonalcoholic steatohepatitis (NASH) is a common cause of chronic
liver disease. Clinical trials use the NASH Clinical Research Network (CRN) system for …

Accurate noninvasive tests (NITs) are needed to replace liver biopsy for identifying
advanced fibrosis caused by nonalcoholic steatohepatitis (NASH). We analyzed screening …

Background & Aim Fibrosis is an independent predictor of death in nonalcoholic
steatohepatitis (NASH). We assessed the associations between histologic and noninvasive …

Nonalcoholic steatohepatitis (NASH) can lead to complications such as liver failure, cirrhosis
and hepatocellular carcinoma. The diagnostic gold standard for NASH is liver biopsy; …

Background & Aims Among the large population of patients with non-alcoholic fatty liver
disease (NAFLD), identifying those with fibrotic non-alcoholic steatohepatitis (Fibro-NASH) …

Nonalcoholic fatty liver disease (NAFLD) is one of the major causes of chronic liver injury.
NAFLD includes a wide range of clinical conditions from simple steatosis to nonalcoholic …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the
United States, and its prevalence is increasing worldwide. It currently affects approximately …

Hepatocellular injury and inflammation are believed to be the primary drivers of fibrogenesis
that ultimately lead to cirrhosis in patients with nonalcoholic steatohepatitis (NASH). This …